Drug Profile
ET 002
Latest Information Update: 10 Nov 2010
Price :
$50
*
At a glance
- Originator Endocrine Technology LLC
- Developer Endocrine Technology
- Class
- Mechanism of Action Complement factor D inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease; Autoimmune disorders; Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus; Type 1 diabetes mellitus
Most Recent Events
- 18 Feb 2002 Available for licensing worldwide (ashah@optonline.net)
- 18 Feb 2002 Preclinical development for Alzheimer's disease in USA (Unknown route)
- 18 Feb 2002 Preclinical development for Autoimmune disorders in USA (Unknown route)